Annalisa Paviglianiti, Mathilde Fekom, Khalid Halahleh, Malek Benakli, Mahmoud Aljurf, Sebastian Giebel, Pierluigi Zinzani, Raffaella Cerretti, Krimo Bouabdallah, Jean El-Cheikh, Saveria Capria, Christof Scheid, Maurizio Musso, Anne Huynh, Hervé Ghesquieres, Charalampia Kyriakou, Alina Tanase, Anna Sureda, Ali Bazarbachi
{"title":"BEAM versus EAM, FEAM, BeEAM, and TEAM: exploring conditioning strategies in autologous stem cell transplantation for Hodgkin lymphoma a retrospective study of the LWP of EBMT.","authors":"Annalisa Paviglianiti, Mathilde Fekom, Khalid Halahleh, Malek Benakli, Mahmoud Aljurf, Sebastian Giebel, Pierluigi Zinzani, Raffaella Cerretti, Krimo Bouabdallah, Jean El-Cheikh, Saveria Capria, Christof Scheid, Maurizio Musso, Anne Huynh, Hervé Ghesquieres, Charalampia Kyriakou, Alina Tanase, Anna Sureda, Ali Bazarbachi","doi":"10.1038/s41409-026-03043-4","DOIUrl":"https://doi.org/10.1038/s41409-026-03043-4","url":null,"abstract":"<p><p>BEAM (carmustine, etoposide, cytarabine, and melphalan) remains the most used chemotherapy for autologous hematopoietic stem cell transplantation (HSCT) in chemosensitive relapsed Hodgkin's lymphoma (HL). Nevertheless, alternatives have been developed to overcome drugs availability, costs, or potential toxicities. These include BeEAM (substitute carmustine with bendamustine), FEAM (using fotemustine instead of carmustine), TEAM (incorporating thiotepa instead of carmustine) and EAM (without bendamustine, fotemustine, thiotepa or carmustine). We analysed 13207 adults with HL who underwent HSCT in EBMT centers from 2010 to 2022. Chemotherapy was BEAM in 77% (n = 10167), FEAM in 13% (n = 1702), BeEAM in 6% (n = 729), TEAM in 3% (n = 365), and EAM in 2% (n = 244). In multivariable analysis, BeEAM was associated with decreased overall survival (OS) (HR 1.61, p = 0.003) and progression free survival (PFS) (HR 1.48, p < 0.001), higher relapse incidence (RI) (HR 1.43, p < 0.001) and non-relapse mortality (NRM) (HR 1.85, p = 0.04). EAM regimen was also associated with decreased OS (HR 1.55, p = 0.019). Propensity score matching was performed as a sensitivity analysis and confirmed the results of the multivariable analysis. We observed poorer outcomes in patients who received bendamustine in our cohort.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lars Klingen Gjærde, Christophe Peczynski, William Boreland, Henrik Sengeløv, Didier Blaise, Tobias Gedde-Dahl, Igor Wolfgang Blau, Jonathan Bordat, Thomas Schroeder, Nicolaus Kröger, Francesca Kinsella, Stephan Mielke, Matthias Eder, Fabio Ciceri, Donal P McLornan, Helene Schoemans, Charlotte Graham, Alberto Mussetti, Zinaida Peric, Ivan Moiseev, Olaf Penack
{"title":"GvHD prophylaxis in elderly patients: post-transplant cyclophosphamide or ATG? A study by the EBMT transplant complications working party.","authors":"Lars Klingen Gjærde, Christophe Peczynski, William Boreland, Henrik Sengeløv, Didier Blaise, Tobias Gedde-Dahl, Igor Wolfgang Blau, Jonathan Bordat, Thomas Schroeder, Nicolaus Kröger, Francesca Kinsella, Stephan Mielke, Matthias Eder, Fabio Ciceri, Donal P McLornan, Helene Schoemans, Charlotte Graham, Alberto Mussetti, Zinaida Peric, Ivan Moiseev, Olaf Penack","doi":"10.1038/s41409-026-03062-1","DOIUrl":"https://doi.org/10.1038/s41409-026-03062-1","url":null,"abstract":"<p><p>Allogeneic hematopoietic cell transplantation (allo‑HCT) has become increasingly feasible in older patients with hematologic malignancies, yet the optimal graft‑versus‑host disease (GvHD) prophylaxis in this population remains uncertain. We compared post‑transplant cyclophosphamide (PTCy) with anti‑thymocyte globulin (ATG) in patients aged ≥60 years undergoing reduced‑intensity conditioning (RIC) peripheral blood stem cell allo‑HCT, using EBMT registry data from 2016 to 2022. A total of 7507 patients were included: 1418 matched sibling donors (MSD), 5051 matched unrelated donors (MUD), and 1038 mismatched unrelated donor (MMUD) transplants. In MSD recipients aged >65 years, PTCy was associated with reduced relapse, improved progression‑free survival (PFS), and superior GvHD‑ and relapse‑free survival (GRFS). However, in MSD recipients aged 60-65 years, these outcomes did not differ significantly between PTCy and ATG. Among MUD recipients, PTCy was associated with lower relapse and chronic GvHD, and a higher PFS, GRFS, and overall survival. In MMUD transplants, outcomes were not significantly different. Our findings indicate that PTCy is a safe and effective alternative to ATG in older allo‑HCT recipients, especially in MUD transplants and in MSD recipients aged >65 years, but the findings should be interpreted cautiously given their observational nature and patient heterogeneity. Further studies are warranted to assess long‑term outcomes.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Micha Srour, Adeline Dujardin, David Beauvais, Paul Chauvet, Valérie Coiteux, Léonardo Magro, Nicolas Gazeau, Serge Alfandari, Fanny Moreau, Pascal Odou, Ibrahim Yakoub-Agha, Nicolas Simon
{"title":"Safety of letermovir-triazole co-administration regarding the risk of invasive fungal infection in allogeneic hematopoietic cell transplantation patients.","authors":"Micha Srour, Adeline Dujardin, David Beauvais, Paul Chauvet, Valérie Coiteux, Léonardo Magro, Nicolas Gazeau, Serge Alfandari, Fanny Moreau, Pascal Odou, Ibrahim Yakoub-Agha, Nicolas Simon","doi":"10.1038/s41409-026-03052-3","DOIUrl":"https://doi.org/10.1038/s41409-026-03052-3","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Udo Holtick, Elisa Sala, Katharina Egger-Heidrich, Mareike Verbeek, Silke Heidenreich, Alexander Denk, Giuliano Filippini Velazquez, Christina Rautenberg, Helene Schmeller, Lasse Jost, Tim Richardson, Christof Scheid, Katrin Strauss, Franziska Taube, Katharina Nickel, Christoph Schmid, Sara Jennrich, Tobias A W Holderried, Friedrich Stölzel, Laurenz Steiner, Marius Dohse, Mohamad-Kamal Yaakoub, Normann Steiner, Olaf Penack, Darina Kodzhabasheva, Jochen J Frietsch, Matthias Stelljes, Caroline Pabst, Ina Rudolph, Guido Kobbe, Claudia Wehr, Kristina Maas-Bauer, Robert Zeiser, Daniel Wolff, Matthias A Fante
{"title":"Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic GVHD: results from a multicenter retrospective analysis of a large German-Austrian cohort of the belumosudil MAP.","authors":"Udo Holtick, Elisa Sala, Katharina Egger-Heidrich, Mareike Verbeek, Silke Heidenreich, Alexander Denk, Giuliano Filippini Velazquez, Christina Rautenberg, Helene Schmeller, Lasse Jost, Tim Richardson, Christof Scheid, Katrin Strauss, Franziska Taube, Katharina Nickel, Christoph Schmid, Sara Jennrich, Tobias A W Holderried, Friedrich Stölzel, Laurenz Steiner, Marius Dohse, Mohamad-Kamal Yaakoub, Normann Steiner, Olaf Penack, Darina Kodzhabasheva, Jochen J Frietsch, Matthias Stelljes, Caroline Pabst, Ina Rudolph, Guido Kobbe, Claudia Wehr, Kristina Maas-Bauer, Robert Zeiser, Daniel Wolff, Matthias A Fante","doi":"10.1038/s41409-026-03054-1","DOIUrl":"https://doi.org/10.1038/s41409-026-03054-1","url":null,"abstract":"<p><p>Chronic graft-versus-host disease (GvHD) is a significant risk factor for late morbidity and mortality after allogeneic stem cell transplantation. In Europe, so far there were no standard treatment options available after failure of corticosteroids and ruxolitinib. The selective ROCK-2 inhibitor belumosudil, a novel FDA-, and recently EMA-approved agent, has shown efficacy in phase-2 trials and had been made available to German and Austrian patients within a managed-access program (MAP). In a retrospective multicenter study, we analyzed 144 patients with predominately severe chronic GvHD (72%) receiving belumosudil within the MAP after a median of four prior therapeutic agents. The objective response rate at one and six months was partial remission or better in 53 and 52 patients (37% and 56%). Responses were observed across all organ systems. Median time to response was 1.3 months. At six months, steroids could be discontinued in 35% and reduced in 33% of patients. Failure-free survival was 81.9% and 75.8% at six and nine months. Six months overall survival was 96.9%. Treatment-emergent adverse reactions CTCAE grade III-IV were mostly infectious complications and occurred in 28 patients (22%). This retrospective analysis of a large real-world cohort demonstrates efficacy and safety of belumosudil in refractory chronic GvHD patients.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Madhavi Lakkaraja, Audrey Mauguen, Kinga Hosszu, Devin McAvoy, Valerie Stewart, Gabrielle Schmidt, John E Levine, Miguel-Angel Perales, Sergio A Giralt, K Scott Baker, Jaap Jan Boelens
{"title":"ATG exposure in T replete transplant for hematological malignancies: Real world analysis from BMT CTN 1202.","authors":"Madhavi Lakkaraja, Audrey Mauguen, Kinga Hosszu, Devin McAvoy, Valerie Stewart, Gabrielle Schmidt, John E Levine, Miguel-Angel Perales, Sergio A Giralt, K Scott Baker, Jaap Jan Boelens","doi":"10.1038/s41409-026-03032-7","DOIUrl":"https://doi.org/10.1038/s41409-026-03032-7","url":null,"abstract":"<p><p>Traditional weight-based dosing results in variable rabbit anti-thymocyte globulin (rATG) clearance, delaying CD4+Tcell-immune-reconstitution (CD4 + IR) and impacting outcomes. In a retrospective pharmacokinetic/pharmacodynamic analysis of patients undergoing first T-replete hematopoietic cell transplantation (HCT), enrolled on BMT CTN 1202, we estimated post-HCT rATG-exposures as area under the curve (arbitrary unit per day/milliliter [AUxd/mL]) using a validated pharmacokinetic-model. Results were compared to patients who did not receive rATG. Previously defined post-HCT rATG-exposure groups: A: < 30, B:30-55 and C: ≥ 55 AUxd/mL were correlated with outcomes of interest using cox-proportional-hazard and cause-specific-hazards models. 325 patients (median age 51 years) were included: 228 received rATG. Median post-HCT rATG-exposure was 44.1 (Range 6.2-125.0). Among patients who received rATG, higher exposure correlated with worse five-year overall survival (OS) (no-ATG:51%; group A:67%; B:49%; C:34%, p = 0.01), higher five-year relapse incidence (no-ATG:31%; A:27%; B: 42%; C: 58%, p < 0.001) and lower CD4 + IR (no-ATG:64%; A:73%; B:51%; C:19%, p = 0.001). Grade 2-4 acute graft versus host disease (GVHD) rates were: no-ATG:40% ; A:26%, B:39%, C:35%, (p = 0.44). Any rATG-exposure was associated with lower moderate/severe chronic GVHD (HR:0.63, p = 0.025). Low post-HCT rATG-exposure ( < 30AUxd/mL) but not absent correlated with higher OS, lower relapse, and lower GVHD related deaths. Model-based-dosing could be used to target optimal post-HCT rATG-exposure and improve HCT outcomes.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antonio Martin Jimenez Jimenez, Diderik-Jan Eikema, Linda Koster, Joe Tuffnell, Alexander Kulagin, Jan Vydra, Nicolaus Kröger, Khaled Halahleh, Elena Parovichnikova, He Huang, Victoria Potter, Tobias Gedde-Dahl, Péter Reményi, Jakob Passweg, Mariya Koc, Ben Carpenter, Werner Rabitsch, Raffaella Cerretti, Francesco Onida, Carmelo Gurnari, Christof Scheid, Joanna Drozd-Sokolowska, Kavita Raj, Marie Robin, Donal P McLornan
{"title":"Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome in young adults: A retrospective study on behalf of the EBMT Chronic Malignancies Working Party.","authors":"Antonio Martin Jimenez Jimenez, Diderik-Jan Eikema, Linda Koster, Joe Tuffnell, Alexander Kulagin, Jan Vydra, Nicolaus Kröger, Khaled Halahleh, Elena Parovichnikova, He Huang, Victoria Potter, Tobias Gedde-Dahl, Péter Reményi, Jakob Passweg, Mariya Koc, Ben Carpenter, Werner Rabitsch, Raffaella Cerretti, Francesco Onida, Carmelo Gurnari, Christof Scheid, Joanna Drozd-Sokolowska, Kavita Raj, Marie Robin, Donal P McLornan","doi":"10.1038/s41409-026-03036-3","DOIUrl":"https://doi.org/10.1038/s41409-026-03036-3","url":null,"abstract":"<p><p>Myelodysplastic syndromes (MDS) in young adults are uncommon and underrepresented in transplant cohorts. We evaluated 697 patients aged 18-40 years who underwent first allogeneic hematopoietic cell transplantation (allo-HCT) reported to the EBMT between 2016 and 2021. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and graft-versus-host disease (GVHD). With a median follow-up of 2.8 years, 3-year OS and PFS were 69% (95% CI, 65-73) and 62% (58-66), respectively. At 3 years, CIR and NRM were 20% (16-23) and 18% (15-21). Grade II-IV acute GVHD occurred in 28% (25-32) by day +100, while chronic GVHD and extensive chronic GVHD occurred in 38% (34-42) and 18% (14-21) at 3 years. In multivariable analysis, very-poor cytogenetic risk was associated with inferior OS (HR 2.81, 95% CI 1.77-4.45). Haploidentical donors and reduced-intensity conditioning were also associated with inferior survival. Patients younger than 30 years had superior PFS, whereas outcomes with matched sibling and matched unrelated donors were comparable. These findings support the feasibility of allo-HCT in young adults with MDS and may help inform risk-adapted transplant approaches.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sergi Camarillas, Anna Alonso-Saladrigues, Víctor Navarro, Júlia Marsal, Águeda Molinos, Javier Delgado, Blanca Herrero, Alex Rampotas, Claire Roddie, Veit Bücklein, Marion Subklewe, Mario Sánchez-Salinas, Berta González-Martínez, Ana África Martin, Anna Torrent, Antonio Pérez-Martínez, Gloria Iacoboni, Susana Rives, Pere Barba
{"title":"Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy.","authors":"Sergi Camarillas, Anna Alonso-Saladrigues, Víctor Navarro, Júlia Marsal, Águeda Molinos, Javier Delgado, Blanca Herrero, Alex Rampotas, Claire Roddie, Veit Bücklein, Marion Subklewe, Mario Sánchez-Salinas, Berta González-Martínez, Ana África Martin, Anna Torrent, Antonio Pérez-Martínez, Gloria Iacoboni, Susana Rives, Pere Barba","doi":"10.1038/s41409-026-03057-y","DOIUrl":"https://doi.org/10.1038/s41409-026-03057-y","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
